News & Updates

Add-on toripalimab yields survival benefit in advanced, metastatic ESCC with manageable toxicity

01 Jun 2022 by

In the first-line treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC), adding the anti-PD-1 monoclonal antibody toripalimab to a standard chemotherapy regimen can significantly cut the risk of progression or death without an increase in adverse events, according to the prespecified analysis of the phase III JUPITER-06 trial.

Add-on toripalimab yields survival benefit in advanced, metastatic ESCC with manageable toxicity

01 Jun 2022

Cannabidivarin safe, reduces seizure frequency in paediatric MECP2-related Rett syndrome

01 Jun 2022

Treatment with a nonhallucinogenic phytocannabinoid, cannabidivarin, is well tolerated in children with Rett syndrome (RTT), according to data from a phase 1 trial. Moreover, it improves seizure control in those whose disease is caused by methyl-CpG-binding protein 2 (MECP2) pathogenic variants.

Cannabidivarin safe, reduces seizure frequency in paediatric MECP2-related Rett syndrome

01 Jun 2022

Antipsychotics work against major depressive disorder, with caveats

31 May 2022 by

Patients with major depressive disorder (MDD) generally achieve satisfactory treatment response with antipsychotic treatment, used either as monotherapy or adjunctively, a meta-analysis has shown. However, this benefit comes with an increased risk of adverse events.

Antipsychotics work against major depressive disorder, with caveats

31 May 2022

Monkeypox scare grips countries

31 May 2022 by

Cases of the rare monkeypox viral disease have been detected in at least 12 countries and experts are cautiously concerned about yet another health disaster.

Monkeypox scare grips countries

31 May 2022

INCREASE OLE data reflect long-term benefit of inhaled treprostinil for PH-ILD

31 May 2022 by

Findings from the open-label extension (OLE) phase of the INCREASE study boost the efficacy and safety of inhaled treprostinil for pulmonary hypertension due to interstitial lung disease (PH-ILD).

INCREASE OLE data reflect long-term benefit of inhaled treprostinil for PH-ILD

31 May 2022

Clozapine-induced gastrointestinal hypomotility poses serious morbidity, mortality risks

31 May 2022

Around 75 percent of patients on clozapine develop treatment-induced gastrointestinal hypomotility (CIGH), which contributes to substantial risks of serious morbidity and mortality, a study reports.

Clozapine-induced gastrointestinal hypomotility poses serious morbidity, mortality risks

31 May 2022

Original New Drug Application Approvals by US FDA (16 - 31 May 2022

31 May 2022

New drug applications approved by US FDA as of 16-31 May 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 31 May 2022

31 May 2022

MS patients on certain DMTs may have limited protection from COVID-19 vax

30 May 2022 by

The overall rate of hospitalization for COVID-19 is low among patients with multiple sclerosis (MS) treated with disease-modifying therapies (DMTs) who have been vaccinated against COVID-19, according to a prospective study from England. However, patients on ocrelizumab or fingolimod have elevated hospitalization rates.

MS patients on certain DMTs may have limited protection from COVID-19 vax

30 May 2022

$BLU-5937 may SOOTHE refractory cough$

BLU-5937 may SOOTHE refractory cough

30 May 2022 by

Individuals with refractory chronic cough (RCC) may find relief in BLU-5937, a selective P2X3 antagonist under development which showed favourable efficacy in reducing cough frequency in the phase IIb SOOTHE trial.

BLU-5937 may SOOTHE refractory cough

30 May 2022

Jaw osteonecrosis rare following denosumab use

30 May 2022

Though relatively rare, medication-related osteonecrosis of the jaw (MRONJ) can nevertheless occur after denosumab treatment, even in the absence of invasive dental treatment, reports a recent study.

Jaw osteonecrosis rare following denosumab use

30 May 2022

News & Updates

Filter by Specialty:

Specialty:

Add-on toripalimab yields survival benefit in advanced, metastatic ESCC with manageable toxicity

Add-on toripalimab yields survival benefit in advanced, metastatic ESCC with manageable toxicity

Cannabidivarin safe, reduces seizure frequency in paediatric MECP2-related Rett syndrome

Cannabidivarin safe, reduces seizure frequency in paediatric MECP2-related Rett syndrome

Antipsychotics work against major depressive disorder, with caveats

Antipsychotics work against major depressive disorder, with caveats

Monkeypox scare grips countries

Monkeypox scare grips countries

INCREASE OLE data reflect long-term benefit of inhaled treprostinil for PH-ILD

INCREASE OLE data reflect long-term benefit of inhaled treprostinil for PH-ILD

Clozapine-induced gastrointestinal hypomotility poses serious morbidity, mortality risks

Clozapine-induced gastrointestinal hypomotility poses serious morbidity, mortality risks

Original New Drug Application Approvals by US FDA (16 - 31 May 2022

Original New Drug Application Approvals by US FDA (16 - 31 May 2022

MS patients on certain DMTs may have limited protection from COVID-19 vax

MS patients on certain DMTs may have limited protection from COVID-19 vax

BLU-5937 may SOOTHE refractory cough

BLU-5937 may SOOTHE refractory cough

Jaw osteonecrosis rare following denosumab use

Jaw osteonecrosis rare following denosumab use